Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.
作者信息
Deschênes-Simard Xavier, Pennisi Martina, Perales Miguel-Angel, Shah Gunjan L, Zelenetz Andrew D, Yahalom Joachim, Imber Brandon S, Santomasso Bianca D, Dahi Parastoo B
机构信息
Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, University of Montreal, Montréal, Quebec, Canada.
出版信息
Leuk Lymphoma. 2025 Mar;66(3):535-540. doi: 10.1080/10428194.2024.2430703. Epub 2024 Nov 20.
Abstract
摘要
相似文献
1
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.严重毒性，但在大B细胞淋巴瘤中免疫检查点抑制剂治疗后CAR T细胞长期持续存在。
Leuk Lymphoma. 2025 Mar;66(3):535-540. doi: 10.1080/10428194.2024.2430703. Epub 2024 Nov 20.
2
Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model.IL15-IL15Rα 耦联物增强 CD19 CAR-T 细胞的抗肿瘤活性，但在免疫活性淋巴瘤小鼠模型中显示出长期毒性。
J Immunother Cancer. 2024 Jul 1;12(7):e008572. doi: 10.1136/jitc-2023-008572.
3
Immune checkpoint blockade and CAR T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma: Challenges and opportunities.T细胞/组织细胞丰富的大B细胞淋巴瘤中的免疫检查点阻断和嵌合抗原受体T细胞疗法：挑战与机遇
Heliyon. 2024 Sep 18;10(18):e38023. doi: 10.1016/j.heliyon.2024.e38023. eCollection 2024 Sep 30.
4
Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.嵌合抗原受体 T 细胞治疗后程序性细胞死亡受体 1 抑制剂维持治疗复发/难治性 B 细胞非霍奇金淋巴瘤的疗效。
Cell Oncol (Dordr). 2024 Aug;47(4):1425-1440. doi: 10.1007/s13402-024-00940-y. Epub 2024 Apr 2.
5
CAR-T cell persistence in the treatment of leukemia and lymphoma.嵌合抗原受体 T 细胞在白血病和淋巴瘤治疗中的持久性。
Leuk Lymphoma. 2021 Nov;62(11):2587-2599. doi: 10.1080/10428194.2021.1913146. Epub 2021 Apr 19.
6
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T.与复发/难治性B细胞急性淋巴细胞白血病中CAR-T细胞持久性相关的持久缓解以及初始CAR-T细胞的长期持久潜力。
Mol Ther Oncolytics. 2023 Apr 20;29:107-117. doi: 10.1016/j.omto.2023.04.003. eCollection 2023 Jun 15.
7
Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS.病例报告：嵌合抗原受体T细胞疗法背景下与检查点抑制相关的严重皮肤不良事件：超越细胞因子释放综合征
Front Oncol. 2023 Jun 15;13:1171031. doi: 10.3389/fonc.2023.1171031. eCollection 2023.
8
CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma.嵌合抗原受体 T 细胞（CAR T 细胞）的持久性与 B 细胞淋巴瘤患者的改善结局相关。
Int J Mol Sci. 2023 Mar 16;24(6):5688. doi: 10.3390/ijms24065688.
9
Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.西达本胺联合 PD-1 阻断治疗 CAR-T 治疗失败风险高的难治/复发侵袭性大 B 细胞淋巴瘤。
Int Immunopharmacol. 2024 May 30;133:112014. doi: 10.1016/j.intimp.2024.112014. Epub 2024 Apr 13.
10
How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.嵌合抗原受体 T 细胞治疗失败后弥漫性大 B 细胞淋巴瘤的治疗策略
Curr Treat Options Oncol. 2021 Oct 26;22(12):112. doi: 10.1007/s11864-021-00906-4.
本文引用的文献
1
Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy.CAR T 细胞治疗后急性脊髓病的临床特征、病理生理学和治疗。
Blood. 2024 Nov 14;144(20):2083-2094. doi: 10.1182/blood.2024025679.
2
PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.PD-1 下调通过维持细胞记忆表型和减少衰竭来增强 CAR-T 细胞的抗肿瘤效率。
J Immunother Cancer. 2024 Apr 8;12(4):e008429. doi: 10.1136/jitc-2023-008429.
3
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.抗 PD-L1 抗体起始时机影响 CD19 CAR T 细胞治疗大 B 细胞淋巴瘤的疗效/毒性。
Blood Adv. 2024 Jan 23;8(2):453-467. doi: 10.1182/bloodadvances.2023011287.
4
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).ZUMA-5 研究：复发/难治性惰性非霍奇金淋巴瘤中 axicabtagene ciloleucel 的 3 年随访分析。
Blood. 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243.
5
Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS.病例报告：嵌合抗原受体T细胞疗法背景下与检查点抑制相关的严重皮肤不良事件：超越细胞因子释放综合征
Front Oncol. 2023 Jun 15;13:1171031. doi: 10.3389/fonc.2023.1171031. eCollection 2023.
6
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.阿基仑赛治疗大 B 细胞淋巴瘤的总生存。
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5.
7
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.CAR-T 治疗失败后接受检查点抑制治疗侵袭性 B 细胞淋巴瘤的疗效：来自 15 家美国机构的结果。
Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016.
8
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.avelumab 和利妥昔单抗在 R-CHOP 前对弥漫性大 B 细胞淋巴瘤的免疫启动：Ⅱ期 AvR-CHOP 研究。
Leukemia. 2023 May;37(5):1092-1102. doi: 10.1038/s41375-023-01863-7. Epub 2023 Mar 11.
9
How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity.我如何治疗 CAR T 细胞治疗相关神经毒性的独特且难以管理的病例。
Blood. 2023 May 18;141(20):2443-2451. doi: 10.1182/blood.2022017604.
10
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.ZUMA-1 的 5 年随访结果支持 axi-cel 在难治性大 B 细胞淋巴瘤中的治疗潜力。
Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893.
Zotero 插件